Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus

NCT06727721 PHASE2 RECRUITING

Umbilical cord mesenchymal stem cell injection expressing OCN19, while playing the role of MSCs, can directly stimulate the expression of insulin gene and the division and proliferation of islet beta cells, which is expected to further enhance the therapeutic effect of stem cells. In non-clinical studies, it was found that MSCs expressing OCN19 had better hypoglycemic effect than MSCs

Details

Lead sponsor	Lu jin ，MD
Phase	PHASE2
Status	RECRUITING
Enrolment	10
Start date	Mon Nov 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diabetes
• Type 2 Diabetes

Interventions

• mesenchymal stem cells with OCN-19
• Mesenchymal stem cells
• albumin injection

Countries

China